

# Jo-Anne H Young

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9183694/publications.pdf>

Version: 2024-02-01

151  
papers

21,372  
citations

28190

55  
h-index

12910

131  
g-index

156  
all docs

156  
docs citations

156  
times ranked

15337  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early <i>Clostridioides difficile</i> infection characterizations, risks, and outcomes in allogeneic hematopoietic stem cell and solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2022, 24, e13720.	0.7	8
2	<i>Clostridioides difficile</i> infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study. <i>Transplant Infectious Disease</i> , 2022, 24, e13770.	0.7	3
3	2021 Acknowledgment of CMR Reviewers. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0024021.	5.7	0
4	Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non- <i>fumigatus</i> ): A multicentre, non-interventional registry study. <i>Mycoses</i> , 2022, 65, 186-198.	1.8	7
5	Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 509.e1-509.e11.	0.6	3
6	Bloodstream Infections in Hematologic Malignancy Patients With Fever and Neutropenia: Are Empirical Antibiotic Therapies in the United States Still Effective?. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	11
7	Both "Small Ball" and "Big Inning" Teams Are Progressing the Value of Antifungal Prophylaxis Among Patients With Hematologic Malignancy. <i>Clinical Infectious Diseases</i> , 2021, 72, 1764-1766.	2.9	0
8	Prophylactic Foscarnet for Human Herpesvirus 6: Effect on Hematopoietic Engraftment after Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 84.e1-84.e5.	0.6	7
9	A Review of Infections After Hematopoietic Cell Transplantation Requiring PICU Care: Transplant Timeline Is Key. <i>Frontiers in Pediatrics</i> , 2021, 9, 634449.	0.9	10
10	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e246-e257.	4.6	167
11	Beginning to understand clinical events and immune responses of hematopoietic cell transplant recipients receiving SARS-CoV-2 vaccination. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 700-701.	0.6	2
12	Aspergillus Infections. <i>New England Journal of Medicine</i> , 2021, 385, 1496-1509.	13.9	74
13	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>Infection and Immunity</i> , 2020, 88, .	1.0	0
14	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>Microbiology Spectrum</i> , 2020, 8, .	1.2	0
15	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	0
16	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>Journal of Virology</i> , 2020, 94, .	1.5	0
17	Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2020, 2020, 1-12.	0.7	0
18	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>Journal of Bacteriology</i> , 2020, 202, .	1.0	0

#	ARTICLE	IF	CITATIONS
19	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>Microbiology and Molecular Biology Reviews</i> , 2020, 84, .	2.9	0
20	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>Journal of Microbiology and Biology Education</i> , 2020, 21, .	0.5	2
21	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>MSystems</i> , 2020, 5, .	1.7	0
22	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>Microbiology Resource Announcements</i> , 2020, 9, .	0.3	0
23	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>MBio</i> , 2020, 11, .	1.8	3
24	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	1
25	Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 766-769.	2.3	46
26	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>Applied and Environmental Microbiology</i> , 2020, 86, .	1.4	1
27	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>MSphere</i> , 2020, 5, .	1.3	1
28	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>Molecular and Cellular Biology</i> , 2020, 40, .	1.1	0
29	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	5.7	1
30	Early <i>E. casseliflavus</i> gut colonization and outcomes of allogeneic hematopoietic cell transplantation. <i>PLoS ONE</i> , 2019, 14, e0220850.	1.1	4
31	Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2474-2481.	2.0	30
32	Preventing Measles in Immunosuppressed Cancer and Hematopoietic Cell Transplantation Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e321-e330.	2.0	26
33	Mixed vs full donor engraftment early after hematopoietic cell transplant: Impact on incidence and control of cytomegalovirus infection. <i>Transplant Infectious Disease</i> , 2019, 21, e13070.	0.7	4
34	Management of Infectious Diseases in Stem Cell Transplantation and Hematologic Malignancy. <i>Infectious Disease Clinics of North America</i> , 2019, 33, xiii-xv.	1.9	6
35	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1254-1265.	1.3	47
36	Bloodstream Infection Due to Vancomycin-resistant <i>Enterococcus</i> Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1771-1779.	2.9	41

#	ARTICLE	IF	CITATIONS
37	Favorable Outcomes in Patients with Pre-Transplant Gut Colonization with Intrinsically Vancomycin-Resistant Enterococci. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S84-S85.	2.0	0
38	Pretransplant Gut Colonization with Intrinsically Vancomycin-Resistant Enterococci ( <i>E. gallinarum</i> ) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1260-1263.	2.0	15
39	Evaluation and Management of Bacterial and Fungal Infections in Patients with a Hematological Malignancy: A 2018 Update. , 2018, , 1063-1078.		0
40	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 870-881.	2.0	38
41	Toward revision of antimicrobial therapies in hematopoietic stem cell transplantation: target the pathogens, but protect the indigenous microbiota. <i>Translational Research</i> , 2017, 179, 116-125.	2.2	16
42	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>Applied and Environmental Microbiology</i> , 2016, 82, 5479-5480.	1.4	1
43	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 63, e1-e60.	2.9	1,861
44	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>MSystems</i> , 2016, 1, .	1.7	3
45	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>Microbiology and Molecular Biology Reviews</i> , 2016, 80, i-ii.	2.9	1
46	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1636-1645.	2.0	71
47	Typical and Atypical Mycobacterium Infections After Hematopoietic Stem Cell or Solid Organ Transplantation. , 2016, , 381-395.		1
48	Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 63, 433-442.	2.9	295
49	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5109-5110.	1.4	3
50	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>Infection and Immunity</i> , 2016, 84, 2407-2408.	1.0	9
51	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2216-2217.	1.8	7
52	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>Clinical Microbiology Reviews</i> , 2016, 29, i-ii.	5.7	4
53	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>MBio</i> , 2016, 7, .	1.8	16
54	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>MSphere</i> , 2016, 1, .	1.3	5

#	ARTICLE	IF	CITATIONS
55	Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. <i>Transplant Infectious Disease</i> , 2016, 18, 210-215.	0.7	58
56	Similar Invasive Fungal Infection Rates and Survival after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Bone Marrow or Peripheral Blood Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S174-S175.	2.0	0
57	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 828-837.	4.6	528
58	Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis. <i>Bone Marrow Transplantation</i> , 2016, 51, 277-282.	1.3	29
59	Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 359-370.	2.0	127
60	Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. <i>Blood</i> , 2015, 126, 2153-2161.	0.6	184
61	Alternative donor hematopoietic cell transplantation for Fanconi anemia. <i>Blood</i> , 2015, 125, 3798-3804.	0.6	90
62	Preliminary Results from the AdVise Study Evaluating Brincidofovir (CMX001, BCV) for the Treatment of Disseminated and High-Risk Adenovirus (AdV) Infection. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S108-S109.	2.0	6
63	More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S49-S50.	2.0	4
64	Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival. <i>Bone Marrow Transplantation</i> , 2015, 50, 1432-1437.	1.3	92
65	Dasatinib-induced immunosuppression and recurrent respiratory tract infections. <i>Leukemia and Lymphoma</i> , 2015, 56, 2484-2485.	0.6	7
66	Infections in Recipients of Hematopoietic Stem Cell Transplants. , 2015, , 3425-3439.e5.		2
67	Identification of Pathogenic Fungi. <i>Clinical Infectious Diseases</i> , 2014, 59, 1044-1045.	2.9	0
68	A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. <i>Blood</i> , 2014, 124, 2921-2929.	0.6	145
69	Lethal small bowel necrosis due to aspergillosis during acute promyelocytic leukemia induction. <i>American Journal of Hematology</i> , 2013, 88, 329-332.	2.0	5
70	Histoplasmosis After Solid Organ Transplant. <i>Clinical Infectious Diseases</i> , 2013, 57, 1542-1549.	2.9	164
71	Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumab. <i>Leukemia and Lymphoma</i> , 2013, 54, 174-176.	0.6	3
72	Bacteremia in Blood or Marrow Transplantation Patients: Clinical Risk Factors for Infection and Emerging Antibiotic Resistance. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 102-108.	2.0	50

#	ARTICLE	IF	CITATIONS
73	A Randomized Trial of One versus Two Doses of Influenza Vaccine after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 109-116.	2.0	57
74	Enterococcal Bacteremia Is Associated With Increased Risk of Mortality in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2012, 55, 764-770.	2.9	124
75	Human Parainfluenza Virus Infection after Hematopoietic Stem Cell Transplantation: Risk Factors, Management, Mortality, and Changes Over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1580-1588.	2.0	68
76	Recurrence of Clostridium difficile infection after total colectomy in an allogeneic stem cell transplant patient. <i>Bone Marrow Transplantation</i> , 2012, 47, 610-611.	1.3	7
77	No increased mortality from donor or recipient hepatitis B and/or hepatitis C positive serostatus after related donor allogeneic hematopoietic cell transplantation. <i>Transplant Infectious Disease</i> , 2012, 14, 468-478.	0.7	23
78	Alternative Donor Hematopoietic Cell Transplantation for Patients with Fanconi Anemia. <i>Blood</i> , 2012, 120, 3081-3081.	0.6	1
79	Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2011, 52, e56-e93.	2.9	2,434
80	An International Comparison of Current Strategies to Prevent Herpesvirus and Fungal Infections in Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 664-673.	2.0	65
81	Human Herpesvirus 6 Infection after Hematopoietic Cell Transplantation: Is Routine Surveillance Necessary?. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1562-1568.	2.0	87
82	Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 284-292.	4.6	315
83	Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias. <i>Infectious Disorders - Drug Targets</i> , 2011, 11, 3-10.	0.4	17
84	Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 171-183.	1.0	28
85	Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2011, 52, 427-431.	2.9	635
86	The impact of cytomegalovirus infection 1 year after primary renal transplantation. <i>Clinical Transplantation</i> , 2010, 24, 572-577.	0.8	33
87	Impact of Cytomegalovirus (CMV) Reactivation after Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 215-222.	2.0	84
88	Monitoring and Preemptive Rituximab Therapy for Epstein-Barr Virus Reactivation after Antithymocyte Globulin Containing Nonmyeloablative Conditioning for Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 287-291.	2.0	72
89	Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1155-1161.	2.0	37
90	Infections in Recipients of Hematopoietic Cell Transplantation. , 2010, , 3821-3837.		2

#	ARTICLE	IF	CITATIONS
91	Time Trends in Fungal Infections as a Cause of Death in Hematopoietic Stem Cell Transplant Recipients. <i>American Journal of Clinical Pathology</i> , 2009, 132, 746-755.	0.4	31
92	A Multicenter, Double-blind Trial of a High-dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis. <i>Clinical Infectious Diseases</i> , 2009, 48, 1676-1684.	2.9	196
93	Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. <i>Bone Marrow Transplantation</i> , 2009, 43, 237-244.	1.3	37
94	Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. <i>Bone Marrow Transplantation</i> , 2009, 44, 453-455.	1.3	320
95	Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated. <i>Bone Marrow Transplantation</i> , 2009, 44, 495-507.	1.3	77
96	Safe living after hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2009, 44, 509-519.	1.3	44
97	Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. <i>Transplant Infectious Disease</i> , 2009, 11, 89-93.	0.7	116
98	Allogeneic Hematopoietic Cell Transplantation in Human Immunodeficiency Virus-positive Patients with Hematologic Disorders: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 864-871.	2.0	58
99	Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1143-1238.	2.0	1,505
100	Infectious complications of acute and chronic GVHD. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 343-356.	0.7	16
101	Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2008, 46, 327-360.	2.9	2,432
102	Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. <i>Blood</i> , 2008, 111, 5403-5410.	0.6	226
103	Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial. <i>Clinical Infectious Diseases</i> , 2007, 44, 2-12.	2.9	724
104	Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 440-443.	2.0	41
105	Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1106-1115.	2.0	108
106	A Scheme for Defining Cause of Death and Its Application in the T Cell Depletion Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1469-1476.	2.0	126
107	Higher Risk of Cytomegalovirus and Aspergillus Infections in Recipients of T Cell-depleted Unrelated Bone Marrow: Analysis of Infectious Complications in Patients Treated with T Cell Depletion Versus Immunosuppressive Therapy to Prevent Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1487-1498.	2.0	148
108	Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. <i>Haematologica</i> , 2007, 92, 1029-1036.	1.7	57

#	ARTICLE	IF	CITATIONS
109	Cat-scratch disease relapse in a kidney transplant recipient. <i>Pediatric Transplantation</i> , 2007, 11, 105-109.	0.5	22
110	Infectious complications following unrelated cord blood transplantation. <i>Vox Sanguinis</i> , 2007, 92, 070302022831001-???.	0.7	32
111	Fewer early bacterial and viral infections following non-myeloablative vs. myeloablative conditioning for allotransplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 32.	2.0	0
112	Efficacy of posaconazole (POS) vs standard therapy and safety of POS in hematopoietic stem cell transplant (HSCT) recipients vs other patients with aspergillosis. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 137.	2.0	1
113	Treatment of zygomycosis: Posaconazole as a treatment option in 91 cases. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 139.	2.0	0
114	Human Metapneumovirus: Important but Not Currently Diagnosable. <i>Annals of Internal Medicine</i> , 2006, 144, 374.	2.0	5
115	Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. <i>Blood</i> , 2006, 108, 2874-2880.	0.6	257
116	Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. <i>Journal of Infection</i> , 2006, 53, 337-349.	1.7	290
117	Posaconazole as Salvage Therapy for Zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 126-133.	1.4	523
118	Posaconazole Is Effective as Salvage Therapy in Zygomycosis: A Retrospective Summary of 91 Cases. <i>Clinical Infectious Diseases</i> , 2006, 42, e61-e65.	2.9	553
119	Role of new antifungal agents in prophylaxis of mycoses in high risk patients. <i>Current Opinion in Infectious Diseases</i> , 2005, 18, 479-483.	1.3	29
120	Secondary graft failure associated with parainfluenza virus infection following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2005, 35, 425-425.	1.3	5
121	Outcome of CNS and pulmonary enteroviral infections after hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , 2005, 45, 74-75.	0.8	15
122	HspE7 Treatment of Pediatric Recurrent Respiratory Papillomatosis: Final Results of an Open-Label Trial. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2005, 114, 730-737.	0.6	72
123	Reply to Cornely et al.. <i>Clinical Infectious Diseases</i> , 2005, 40, 1699-1701.	2.9	3
124	Serious Infections after Unrelated Donor Transplantation in 136 Children: Impact of Stem Cell Source. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 362-370.	2.0	118
125	Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2004, 39, 1407-1416.	2.9	1,248
126	Genetic Diversity of Human Pathogenic Members of the <i>Fusarium oxysporum</i> Complex Inferred from Multilocus DNA Sequence Data and Amplified Fragment Length Polymorphism Analyses: Evidence for the Recent Dispersion of a Geographically Widespread Clonal Lineage and Nosocomial Origin. <i>Journal of Clinical Microbiology</i> , 2004, 42, 5109-5120.	1.8	201

#	ARTICLE	IF	CITATIONS
127	Reservoir of <i>Candida albicans</i> infection in a vascular bypass graft demonstrates a stable karyotype over six months. <i>Medical Mycology</i> , 2004, 42, 255-260.	0.3	6
128	Specific Detection of Human BK Polyomavirus in Urine Samples of Immunocompromised Patients. <i>Vaccine Journal</i> , 2003, 10, 66-69.	3.2	11
129	A Double-blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2002, 35, 359-366.	2.9	308
130	Is it time for a new look at granulocyte transfusions?. <i>Transfusion</i> , 2002, 42, 1393-1395.	0.8	10
131	Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2002, 30, 945-951.	1.3	40
132	Aspects of Fungal Pathogenesis in Humans. <i>Annual Review of Microbiology</i> , 2001, 55, 743-772.	2.9	139
133	Cytomegalovirus enteritis among hematopoietic stem cell transplant recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 674-679.	2.0	58
134	Infections during mobilizing chemotherapy and following autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001, 28, 1129-1134.	1.3	31
135	Symmetric Peripheral Gangrene. <i>New England Journal of Medicine</i> , 2001, 344, 1593-1593.	13.9	8
136	A Phase I-II Clinical Trial to Evaluate Removal of CD4 Cells and Partial Depletion of CD8 Cells From Donor Marrow for HLA-Mismatched Unrelated Recipients. <i>Blood</i> , 1999, 94, 2192-2199.	0.6	91
137	Modulation of Neutrophil-mediated Activity Against the Pseudohyphal Form of <i>Candida albicans</i> by Granulocyte Colony-stimulating Factor (G-CSF) Administered In Vivo. <i>Journal of Infectious Diseases</i> , 1999, 179, 1301-1304.	1.9	40
138	Comparison of Interferon- $\gamma$ , Granulocyte Colony-stimulating Factor, and Granulocyte Macrophage Colony-stimulating Factor for Priming Leukocyte-mediated Hyphal Damage of Opportunistic Fungal Pathogens. <i>Journal of Infectious Diseases</i> , 1999, 179, 1038-1041.	1.9	91
139	INFECTIONS IN RECIPIENTS OF BLOOD AND MARROW TRANSPLANTATION. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 1065-1089.	0.9	46
140	Comparison of six extraction techniques for isolation of DNA from filamentous fungi. <i>Medical Mycology</i> , 1998, 36, 299-303.	0.3	157
141	Determinants of Human Immunodeficiency Virus DNA and RNA Shedding in the Anal-Rectal Canal of Homosexual Men. <i>Journal of Infectious Diseases</i> , 1998, 177, 571-578.	1.9	34
142	Itraconazole Therapy for Primary Cutaneous Aspergillosis in Patients with AIDS. <i>Clinical Infectious Diseases</i> , 1998, 27, 643-644.	2.9	17
143	Randomized, Double-blind Clinical Trial of Amphotericin B Colloidal Dispersion vs. Amphotericin B in the Empirical Treatment of Fever and Neutropenia. <i>Clinical Infectious Diseases</i> , 1998, 27, 296-302.	2.9	287
144	The Effect of Prophylactic Fluconazole on the Clinical Spectrum of Fungal Diseases in Bone Marrow Transplant Recipients with Special Attention to Hepatic Candidiasis: An Autopsy Study of 355 Patients. <i>Medicine (United States)</i> , 1998, 77, 246-254.	0.4	188

#	ARTICLE	IF	CITATIONS
145	Nocardiosis After Bone Marrow Transplantation: A Retrospective Study. <i>Clinical Infectious Diseases</i> , 1997, 24, 1154-1160.	2.9	127
146	Development of Fluconazole Resistance in <i>Candida albicans</i> Causing Disseminated Infection in a Patient Undergoing Marrow Transplantation. <i>Clinical Infectious Diseases</i> , 1997, 25, 908-910.	2.9	143
147	Granulocyte Colony-Stimulating Factor Administered In Vivo Augments Neutrophil-Mediated Activity against Opportunistic Fungal Pathogens. <i>Journal of Infectious Diseases</i> , 1997, 175, 1012-1015.	1.9	124
148	Epidemiology of <i>Aspergillus</i> Infections in a Large Cohort of Patients Undergoing Bone Marrow Transplantation. <i>Journal of Infectious Diseases</i> , 1997, 175, 1459-1466.	1.9	717
149	Detection and identification of fungal pathogens in blood by using molecular probes. <i>Journal of Clinical Microbiology</i> , 1997, 35, 1353-1360.	1.8	520
150	Phase I Study of Amphotericin B Colloidal Dispersion for the Treatment of Invasive Fungal Infections after Marrow Transplant. <i>Journal of Infectious Diseases</i> , 1996, 173, 1208-1215.	1.9	106
151	Prophylaxis for Aspergillosis. , 0, , 479-489.		0